Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibody

Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully-humanized IgG2 monoclonal antibody that binds to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on the activated T cells. Binding to CTLA-4 results in inhibition of its association with the ligands B7-1 (CD80) and B7-2 (CD86), thereby preventing the downregulation of T-cell activation and inhibition of tumor growth. The original drug is currently undergoing clinical trials for the treatment of several cancers such as melanoma, mesothelioma and non-small cell lung cancer

Immunogen Sequence:Human CTLA-4

Target Alternative Name:CP-675, CP-675,206, CP-675206 clone 11.2.1, CD; GSE; GRD4; ALPS5; CD152; CTLA4; IDDM12; CELIAC3

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that targets CTLA-4 on activated T-lymphocytes and inhibits the interaction with its ligands CD80 and CD86 and promotes T-cell activation

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.